Ebola: Merck's Ebola vaccine Ervebo shown to offer substantial protection--study

Merck Ebola vaccine Ervebo shown to offer substantial protection | STAT (statnews.com)

Merck Ebola vaccine Ervebo shown to offer substantial protection A study in Lancet Infectious Diseases showed 84% effectiveness in people vaccinated at least 10 days before being exposed to Ebola during 2018-2020 outbreak in Africa. Helen Branswell STAT

Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had been vaccinated at least 10 days before being exposed to the virus, a new study reports. An earlier study had shown that people who were vaccinated but went on to develop the disease were more likely to survive the infection.

...